LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Strona główna・Stock List・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Closed

SectorHealthcare

14.16 -2.14

Buy Sell

Overview

Share price change

24h

Current

Min

14.16

Max

14.41

Key metrics
By Trading Economics
Income	227M
Sales	139M
P/E Sector Avg	5.725 108.767
Profit margin	163.843
Employees	1,780
EBITDA	1.3M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+49.46% upside

Market Stats
By TradingEconomics
Market Cap	2.7B
Previous open	16.3
Previous close	14.16

News Sentiment

By Acuity

50%

149 / 352 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

14.24 / 14.78 Support & Resistance

Hutchison China MediTech Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

27 lut 2026, 23:53 UTC

Hot Stocks

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

27 lut 2026, 22:23 UTC

Acquisitions, Mergers, Takeovers

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

27 lut 2026, 17:55 UTC

Hot Stocks

Toronto Stocks Decline, But Remain On Track for Weekly Gains

27 lut 2026, 23:46 UTC

Acquisitions, Mergers, Takeovers

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

27 lut 2026, 23:33 UTC

Acquisitions, Mergers, Takeovers

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

27 lut 2026, 21:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

27 lut 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

27 lut 2026, 21:30 UTC

Earnings

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

27 lut 2026, 21:30 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

27 lut 2026, 21:20 UTC

Acquisitions, Mergers, Takeovers

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

27 lut 2026, 21:17 UTC

Earnings

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27 lut 2026, 21:10 UTC

Acquisitions, Mergers, Takeovers

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

27 lut 2026, 21:09 UTC

Acquisitions, Mergers, Takeovers

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

27 lut 2026, 21:00 UTC

Earnings

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

27 lut 2026, 20:31 UTC

Acquisitions, Mergers, Takeovers

Netflix Receives $2.8B Termination Fee Under Terminated Warner Bros. Discovery Deal

27 lut 2026, 20:24 UTC

Market Talk

Oil Gains on Increased Risk of U.S.-Iran Conflict -- Market Talk

27 lut 2026, 20:23 UTC

Market Talk

U.S. Natural Gas Futures Post Modest Gains -- Market Talk

27 lut 2026, 20:12 UTC

Market Talk

Nike Seen With Further Challenges in China -- Market Talk

27 lut 2026, 19:44 UTC

Market Talk

Gold Caps Historic Month -- Market Talk

27 lut 2026, 19:39 UTC

Earnings

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27 lut 2026, 19:38 UTC

Earnings

Earnings Could Push the Stock Market Higher. Too Bad About Everything Else. -- Barrons.com

27 lut 2026, 18:53 UTC

Acquisitions, Mergers, Takeovers

Largest U.S. Pension Takes Stake in a Hot Semi Stock, Buys More Nvidia and IonQ -- Barrons.com

27 lut 2026, 18:45 UTC

Earnings

Quantum Computing Is No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

27 lut 2026, 18:45 UTC

Market Talk

Bitcoin Stays Vulnerable in Choppy Geopolitical Situation -- Market Talk

27 lut 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

27 lut 2026, 17:07 UTC

Earnings

Pemex Cuts 4Q Loss As Operating Results Improve

27 lut 2026, 17:00 UTC

Market Talk

Corn Rides Oil Momentum Higher -- Market Talk

27 lut 2026, 16:31 UTC

Market Talk

Canadian Economy Shows Resilience -- Market Talk

27 lut 2026, 16:17 UTC

Market Talk

Canada Economy is Struggling But More Rate Cuts Still a Long Shot -- Market Talk

27 lut 2026, 15:49 UTC

Earnings

Quantum Computing No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

Peer Comparison

Price change

Hutchison China MediTech Ltd ADR Forecast

Price Target

By TipRanks

49.46% upside

12 Months Forecast

Average 22 USD 49.46%

High 22 USD

Low 22 USD

Based on 1 Wall Street analysts offering 12 month price targets forHutchison China MediTech Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Hutchison China MediTech Ltd ADR - Dist in the past 3 months.

Technical Score

By Trading Central

14.24 / 14.78Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

149 / 352 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.